[Skip to Content]
[Skip to Content Landing]
Views 2,313
Citations 0
Clinical Trials Update
May 22/29, 2018

Carvedilol During Chemotherapy

JAMA. 2018;319(20):2069. doi:10.1001/jama.2018.6258

The β-blocker carvedilol had no impact on left ventricular ejection fraction (LVEF) in women with breast cancer undergoing chemotherapy, found a study in the Journal of the American College of Cardiology.

The study enrolled 200 patients with breast cancer who had normal LVEF and were scheduled to receive anthracycline (ANT) chemotherapy. Patients were randomly assigned to receive either carvedilol (median daily dose of 18.4 mg/d) or placebo when starting ANT chemotherapy.